Medical device company Merit Medical Systems (NASDAQ: MMSI) will be announcing earnings results this Wednesday afternoon. Here’s what to expect.
Merit Medical Systems beat analysts’ revenue expectations by 0.8% last quarter, reporting revenues of $355.4 million, up 9.8% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ EPS estimates but a significant miss of analysts’ full-year EPS guidance estimates.
Is Merit Medical Systems a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Merit Medical Systems’s revenue to grow 10.5% year on year to $373.4 million, improving from the 5.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.85 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Merit Medical Systems has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.4% on average.
Looking at Merit Medical Systems’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts’ expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%.
Read our full analysis of Boston Scientific’s results here and Intuitive Surgical’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Merit Medical Systems is down 9.9% during the same time and is heading into earnings with an average analyst price target of $108.73 (compared to the current share price of $84.27).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
